Living diagnostics

In recent years, antimicrobial resistance (AMR) has sprung to the forefront of many medical and political conversations, with the warning that the prevalence of resistant pathogens could lead to a public health crisis. Ranked a top 10 global public health threat by the World Health Organization, it is estimated that 1.27 million deaths occurred in a single year attributable to AMR.

Worldwide escalation in antimicrobial resistance (AMR) has sparked fear of a looming post-antimicrobial era. Antibiotic overuse and inappropriate use—including over-prescribing, inaccurate, and suboptimal prescribing—promotes bacterial evolution and resistance to treatment. Data suggests that there were an estimated 4.95 million deaths associated with bacterial AMR in 2019. The World Bank estimates that AMR could result in 1 trillion dollars in additional healthcare costs by 2050 if actions are not taken now to curb growing resistance.

Osteomyelitis – infection of the bone, and septic arthritis – joint infection, are serious medical conditions that can significantly impact a patient's quality of life. Bone and joint infections, often referred to as (BJIs), are notoriously difficult to treat and successful therapy requires organism-specific antimicrobial therapy at high doses for a prolonged duration.1 Diagnostics can support the identification and management of BJIs, while helping slow the progression of antimicrobial resistance (AMR).

At bioMérieux, we proudly operate at the forefront of diagnostics, supporting customers across the food and drinks industry to help protect consumers and strive for the very highest standards of safety and quality. As we enter 2025, we reflect on the trends we can expect to see in this important sector this year.